GenSight Biologics S.A. GSGTF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -51.08% | -63.91% | 32.10% | 33.88% | -25.62% |
| Total Depreciation and Amortization | 22.75% | 33.15% | -34.17% | -35.87% | -68.35% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,238.46% | 1,352.74% | 224.22% | 215.76% | 111.57% |
| Change in Net Operating Assets | 62.62% | 76.42% | -311.92% | -306.38% | 669.90% |
| Cash from Operations | 35.19% | 29.69% | -31.06% | -27.62% | 64.70% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 96.01% | 95.70% | 5,007.41% | 5,029.63% | -530.00% |
| Cash from Investing | -31.23% | -42.65% | 4,922.22% | 4,944.44% | -563.08% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 50.28% | 50.28% | 63.83% | 63.83% | 13.02% |
| Issuance of Common Stock | 28.31% | 28.31% | 8.61% | 8.61% | -93.29% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 522.03% | 522.03% | 464.16% | 464.16% | -103.33% |
| Cash from Financing | 227.54% | 255.44% | 569.52% | 551.98% | -97.30% |
| Foreign Exchange rate Adjustments | -1,573.33% | -1,688.10% | 98.93% | 98.90% | 104.55% |
| Miscellaneous Cash Flow Adjustments | -- | -- | 20.00% | 0.00% | -- |
| Net Change in Cash | 65.29% | 62.34% | 152.36% | 150.99% | -148.14% |